BCMA-TGF-BETA Insensitive Armored CAR T Cells

Phase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Patients With Relapsed and/or Refractory Multiple Myeloma

What's the purpose of the trial?

This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and efficacy of interleukin-7(IL-7) / interleukin-15 (IL-15) manufactured CAR T cells in adult patients with relapsed and/or refractory myeloma that have failed prior therapies.
Trial status

Not yet accepting

Phase
Phase 1
Enrollment
30
Last Updated
2 weeks ago
Patient Screener

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BCMA-TGFβ CAR-T cells CAR-T therapy is a type of immunotherapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize BCMA-TGFβ (a protein found on myeloma cells) more easily.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.